Munar Pharma

Munar Pharma EV/EBIT

Delisted

The EV/EBIT (Enterprise Value to EBIT) of Munar Pharma (MUN.WA) as of Nov 20, 2026 is -44.65. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -11.55 — a change of 286.69% (lower).

EV/EBIT

-44.65

YoY

286.69%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Munar Pharma is 2024 -44.65 . EV/EBIT (Enterprise Value to EBIT) of Munar Pharma was 2023 -11.55 . It decreases by 286.69% lower compared to the previous year.

The Munar Pharma EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2017
-96.66 PLN
Jan 1, 2018
-1.43 PLN
Jan 1, 2019
-196.55 PLN
Jan 1, 2020
-12.04 PLN
Jan 1, 2021
-16.82 PLN
Jan 1, 2022
97.97 PLN
Jan 1, 2023
-11.55 PLN
Jan 1, 2024
-44.65 PLN
The Munar Pharma EV/EBIT history
YEAREV/EBITYoY
-44.65+286.69%
-11.55-111.79%
97.97-682.59%
-16.82+39.63%
-12.04-93.87%
-196.55+13,644.25%
-1.43-98.52%
-96.66-111.63%
831.43+107.52%
400.65—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Munar Pharma Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Munar Pharma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Munar Pharma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Munar Pharma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Munar Pharma grows earnings faster than its peers.

Munar Pharma Stock analysis

What does Munar Pharma do? No Gravity Games SA generates revenue by providing internet-related services, including content management systems, web shops, and website implementation. The company leverages its own technical infrastructure and programming resources to create and maintain specialized websites for its corporate clients. These digital assets include audiostereo.pl for audio enthusiasts, zagraj.com.pl as an online games portal, and legalneinfo.pl, which serves as an online catalogue of free software. The firm further supports application development and external software development for its corporate clients. Its portfolio extends to sport1.pl, offering information on disciplines such as football, volleyball, basketball, tennis, handball, and winter sports. Additional sites managed by the company include YOYO.pl, an independent provider of free hosting services, as well as chillisport.pl, oboe.pl, legenhit.pl, webtips.pl, xt.pl, and websonda.pl. Munar Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Munar Pharma stock

EV/EBIT (Enterprise Value to EBIT) of Munar Pharma is -44.65 in 2024.

EV/EBIT (Enterprise Value to EBIT) of Munar Pharma changed from -11.55 to -44.65, representing a 286.69% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Munar Pharma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Munar Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Munar Pharma

All Key Metrics — Munar Pharma